PD 98059

Name: PD 98059
Brand: MM

≥98% (HPLC), MAPK pathway inhibitor and AMPK activator, liquid

Synonym(s):

InSolution PD 98059, MEK Inhibitor V

Select a Size

All Photos(1)

About This Item

Empirical Formula (Hill Notation):

C₁₆H₁₃NO₃

CAS Number:

167869-21-8

Molecular Weight:

267.28

UNSPSC Code:

12352200

NACRES:

NA.77

MDL number:

MFCD00671789

Product Name

PD 98059, InSolution, ≥98%, 5 mg/ml, reversible inhibitor of MAP Kinase Kinase (MEK)

SMILES string

Nc1c(cccc1c2[o]c3c([c](c2)=O)cccc3)OC

InChI

1S/C16H13NO3/c1-19-14-8-4-6-11(16(14)17)15-9-12(18)10-5-2-3-7-13(10)20-15/h2-9H,17H2,1H3

InChI key

QFWCYNPOPKQOKV-UHFFFAOYSA-N

assay

≥98% (HPLC)

form

liquid

manufacturer/tradename

Calbiochem^®

storage condition

OK to freeze
protect from light

shipped in

wet ice

storage temp.

−20°C

Quality Level

100

Related Categories

Bioactive Small Molecule Inhibitors

Bioactive Small Molecules

Biochem/physiol Actions

Cell permeable: yes

Primary Target
MAP kinase kinase (MEK)

Product does not compete with ATP.

Reversible: yes

Target IC₅₀: 2 µM in completely blocking the 4-fold increase in MAP kinase activity produced by nerve growth factor in PC12 cells

Disclaimer

Toxicity: Irritant (B)

General description

Selective and cell-permeable inhibitor of MAP kinase kinase (MEK) that acts by inhibiting the activation of MAP kinase and subsequent phosphorylation of MAP kinase substrates. Pretreatment of PC-12 cells with PD 98059 completely blocks the 4-fold increase of MAP kinase activity produced by nerve growth factor (NGF; IC₅₀ = 2 µM); however, it has no effect on NGF-dependent tyrosine phosphorylation of the pp140^trk receptor or its substrate Shc and does not block NGF-dependent activation of PI 3-kinase. Inhibits cell growth and reverses the phenotype of ras-transformed BALB 3T3 mouse fibroblasts and rat kidney cells.

Other Notes

Kültz, D., et al. 1998. J. Biol. Chem.273, 13645.
Dudley, D.T., et al. 1995. Proc. Natl. Acad. Sci. USA92, 7686.
Langlois, W.J., et al. 1995. J. Biol. Chem.270, 25320.
Pang, L., et al. 1995. J. Biol. Chem.270, 13585.
Waters, S.B., et al. 1995. J. Biol. Chem.270, 20883.

Selected Citations
Lee, J., et al. 2009. Cell Stem Cell5, 76.

Packaging

Packaged under inert gas

Physical form

A 5 mg/ml solution of PD 98059 (Cat. No. 513000) in anhydrous DMSO.

Preparation Note

Following initial thaw, aliquot and freeze.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class

10 - Combustible liquids

wgk

WGK 2

flash_point_f

188.6 °F - closed cup - (Dimethylsulfoxide)

flash_point_c

87 °C - closed cup - (Dimethylsulfoxide)

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Glycochenodeoxycholate induces cell survival and chemoresistance via phosphorylation of STAT3 at Ser727 site in HCC.

Jue Wang et al.

Journal of cellular physiology, 235(3), 2557-2568 (2019-09-10)

Glycochenodeoxycholate (GCDA) is closely associated with carcinogenesis and chemoresistance of hepatocellular carcinoma (HCC). Signal transducer and activator of transcription 3 (STAT3), a transcription factor, is involved in various human tumors. Whether GCDA induces chemoresistance through STAT3 and the mechanism of

Repurposing Dipyridamole in Niemann Pick Type C Disease: A Proof of Concept Study.

Rita Pepponi et al.

International journal of molecular sciences, 23(7) (2022-04-13)

Niemann Pick type C disease (NPC) is a rare disorder characterized by lysosomal lipid accumulation that damages peripheral organs and the central nervous system. Currently, only miglustat is authorized for NPC treatment in Europe, and thus the identification of new

Terminal uridyltransferase 7 regulates TLR4-triggered inflammation by controlling Regnase-1 mRNA uridylation and degradation.

Chia-Ching Lin et al.

Nature communications, 12(1), 3878-3878 (2021-07-01)

Different levels of regulatory mechanisms, including posttranscriptional regulation, are needed to elaborately regulate inflammatory responses to prevent harmful effects. Terminal uridyltransferase 7 (TUT7) controls RNA stability by adding uridines to its 3' ends, but its function in innate immune response